Hookipa Pharma Inc (HOOK) Stock Price, Quote & News

Company Profile

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of...

Industry: Biotechnology

Sector: Healthcare

Phone: 431 890 6360

Website: www.hookipapharma.com

Address:

350 Fifth Avenue, 72nd Floor Suite 7240, New York, United States

joe77w Jul. 26 at 5:08 AM

$HOOK 1.28/1.73 liquidation range USD people selling now giving up huge return in the short term because Company, once and if liquidation and dissolution approved, will send money back to holders. Buying below the dollar does mean at least 30 % return with minimal liquidation estimated, otherwise much more, in the best case 95%.

2 · Reply

Wildsens Jul. 25 at 2:11 PM

$HOOK Delisting soon. Better sell your shares.

1 · Reply

superjeffy Jul. 23 at 1:47 PM

$HOOK got out at $1.50 for a loss

0 · Reply

Zampi1 Jul. 22 at 4:56 PM

$HOOK fu**ers!

0 · Reply

Zonata Jul. 21 at 10:42 PM

$HOOK too bad I didn't sold out. Once again I'm getting bitten by a garbage biotech.

0 · Reply

TangoToEvora Jul. 21 at 9:20 PM

$HOOK CROOK

0 · Reply

JB_Research Jul. 21 at 2:16 PM

$HOOK

0 · Reply

Shadowplays Jul. 21 at 10:49 AM

$HOOK hail Mary for gambling

0 · Reply

theSnip3r Jul. 18 at 8:28 PM

$HOOK so is this news bad ??

2 · Reply

TwongStocks Jul. 18 at 8:09 PM

$HOOK News released, trading will resume at 4:35pm ET

0 · Reply

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

Feb 20, 2025, 3:06 PM EST - 5 months ago

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

Jan 10, 2025, 2:00 AM EST - 7 months ago

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

Jan 8, 2025, 11:23 AM EST - 7 months ago

HOOKIPA Pharma Inc - FORM 8 (OPD)

Jan 7, 2025, 4:05 PM EST - 7 months ago

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

Jan 6, 2025, 2:00 AM EST - 7 months ago

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

Jan 2, 2025, 2:00 AM EST - 7 months ago

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Nov 11, 2024, 4:05 PM EST - 9 months ago

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Oct 31, 2024, 9:17 AM EDT - 9 months ago

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

Oct 30, 2024, 7:30 AM EDT - 9 months ago

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Sep 24, 2024, 7:30 AM EDT - 11 months ago

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Sep 17, 2024, 8:00 AM EDT - 11 months ago

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

Aug 30, 2024, 8:00 AM EDT - 1 year ago

HOOKIPA Pharma Announces Board of Directors Changes

Aug 28, 2024, 8:57 AM EDT - 1 year ago

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 1 year ago

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 22, 2024, 8:30 AM EDT - 1 year ago

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

Jul 8, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split

Jul 1, 2024, 4:31 PM EDT - 1 year ago

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Jun 4, 2024, 1:00 PM EDT - 1 year ago

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

May 30, 2024, 4:30 PM EDT - 1 year ago

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting

May 23, 2024, 5:01 PM EDT - 1 year ago

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

May 9, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 25, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

Apr 24, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

Apr 22, 2024, 2:20 PM EDT - 1 year ago

Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts

Apr 16, 2024, 4:30 PM EDT - 1 year ago

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Apr 10, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

Mar 22, 2024, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Mar 6, 2024, 7:01 AM EST - 1 year ago

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

Jan 29, 2024, 8:01 AM EST - 1 year ago

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

Jan 16, 2024, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Dec 21, 2023, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Nov 20, 2023, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Nov 9, 2023, 7:01 AM EST - 1 year ago

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 12:01 PM EDT - 1 year ago

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

Nov 2, 2023, 4:01 PM EDT - 1 year ago

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

Oct 22, 2023, 6:01 AM EDT - 1 year ago

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

Oct 18, 2023, 7:01 AM EDT - 1 year ago

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

Sep 13, 2023, 8:45 AM EDT - 2 years ago

HOOKIPA Announces Executive Leadership Change

Sep 12, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Sep 6, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma to participate in upcoming investor conferences in September

Aug 10, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 3, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

Jun 10, 2023, 5:00 AM EDT - 2 years ago

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 31, 2023, 9:30 PM EDT - 2 years ago

HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

May 31, 2023, 4:45 PM EDT - 2 years ago

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

May 11, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 9, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

May 4, 2023, 7:02 AM EDT - 2 years ago

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

May 4, 2023, 7:01 AM EDT - 2 years ago

HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023

joe77w Jul. 26 at 5:08 AM

2 · Reply

Wildsens Jul. 25 at 2:11 PM

$HOOK Delisting soon. Better sell your shares.

1 · Reply

superjeffy Jul. 23 at 1:47 PM

$HOOK got out at $1.50 for a loss

0 · Reply

Zampi1 Jul. 22 at 4:56 PM

$HOOK fu**ers!

0 · Reply

Zonata Jul. 21 at 10:42 PM

$HOOK too bad I didn't sold out. Once again I'm getting bitten by a garbage biotech.

0 · Reply

TangoToEvora Jul. 21 at 9:20 PM

$HOOK CROOK

0 · Reply

JB_Research Jul. 21 at 2:16 PM

$HOOK

0 · Reply

Shadowplays Jul. 21 at 10:49 AM

$HOOK hail Mary for gambling

0 · Reply

theSnip3r Jul. 18 at 8:28 PM

$HOOK so is this news bad ??

2 · Reply

TwongStocks Jul. 18 at 8:09 PM

$HOOK News released, trading will resume at 4:35pm ET

0 · Reply

TwongStocks Jul. 18 at 8:07 PM

$HOOK Announces intention to voluntarily delist & deregister common stock https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-pharma-announces-intention-voluntarily-delist-and On July 18, 2025, HOOKIPA notified Nasdaq of its intent to voluntarily delist its common stock from Nasdaq. HOOKIPA currently anticipates that it will file with the Securities and Exchange Commission (“SEC”) a Form 25 relating to the delisting and deregistration of its common stock on or about July 29, 2025, and anticipates that the delisting and deregistration under Section 12(b) of its common stock will then become effective on or about August 8, 2025.

0 · Reply

TwongStocks Jul. 18 at 8:04 PM

$HOOK Halted, T1 Pending News

1 · Reply

TrkDvr Jul. 17 at 7:42 PM

$HOOK Reading thru this dissolution plan what I don't get is that Gilead is paying $10M for a specific asset. What about the $40.2 m in cash less debt of $800K less operating expense thru dissolution of approx $6M leaves about $27.4m plus net proceeds from asset sale of $7M = $34M. Please explain!

2 · Reply

gilheydari Jul. 11 at 11:34 PM

$HOOK Three years from date of certification and 1.28-1.72, I I closed my position and will buy back this below $1

0 · Reply

TangoToEvora Jul. 9 at 10:03 PM

$HOOK They should change the handle name from HOOK to CROOK

0 · Reply

superjeffy Jul. 2 at 5:56 PM

$HOOK or cash out now and get your whole $1.28 a share now

1 · Reply

Wildsens Jun. 30 at 9:31 PM

$HOOK New PR. It takes 3 years and you get 1.28 - 1.72 (probably). https://ir.hookipapharma.com/static-files/11f0658d-d3b3-44ca-aaf1-b7a89d34500d#page48

1 · Reply

DollaNugs Jun. 30 at 2:13 PM

$HOOK

0 · Reply

dcljr521 Jun. 30 at 1:41 PM

$HOOK is there any hope left?

0 · Reply

wyoming2020 Jun. 28 at 7:44 PM

$PDSB the circulating dna data is very strong on the MD Anderson trial and the OS is going to be impressive. Little doubt this drug is commercialised but the company is out of money, essentially <$250M. You need a fortune to compete here. Gilead took $HOOK for free essentially. There is little hope the company can afford the $100M+ milestones to Merck Gaa, whom they purchased the rights from years ago. I think we see a return of asset and why I am long $MRK as well. Still here. I'll die on the hill but I am hedging (doubling loss😂 w MRK purchase)

3 · Reply

Wildsens Jun. 16 at 8:21 PM

$HOOK More info: https://ir.hookipapharma.com/static-files/1917964b-7ba3-4a14-ab52-e983843c2ad2

0 · Reply

bavramidis Jun. 11 at 4:32 PM

$HOOK Total POS. I continue to hope for the best but have been in this for years and nothing but down down down. Only reason I'm not selling my entire position is cause I'm down so bad....

2 · Reply

Market Cap	10.91M
Revenue (ttm)	43.95M
Net Income (ttm)	-43.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-98.98%
Debt to Equity Ratio	0.00

Volume	28,000
Avg Vol	141,906
Day's Range	N/A - N/A
Shares Out	12.19M
Stochastic %K	8%
Beta	0.89
Analysts	Hold
Price Target	$2.00